Intercept Pharmaceuticals, Inc. (ICPT) Trading Up 4.5%
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)’s share price was up 4.5% during trading on Wednesday . The stock traded as high as $67.49 and last traded at $68.73. Approximately 1,838,348 shares were traded during trading, an increase of 42% from the average daily volume of 1,294,130 shares. The stock had previously closed at $65.76.
Several equities analysts recently commented on ICPT shares. Cowen and Company reissued a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Monday, June 12th. Wedbush reissued a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Monday, July 31st. BidaskClub raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Jefferies Group LLC reissued a “buy” rating and set a $275.00 price target on shares of Intercept Pharmaceuticals in a research report on Sunday, July 30th. Finally, Zacks Investment Research raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $136.00 price target on the stock in a research report on Tuesday, July 11th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $162.88.
The stock’s 50 day moving average is $93.18 and its 200-day moving average is $110.81. The stock’s market cap is $1.83 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, topping the Zacks’ consensus estimate of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The company had revenue of $30.89 million during the quarter, compared to the consensus estimate of $27.50 million. During the same quarter last year, the company earned ($3.14) EPS. The company’s quarterly revenue was up 459.6% on a year-over-year basis. On average, equities research analysts predict that Intercept Pharmaceuticals, Inc. will post ($13.98) earnings per share for the current year.
In related news, CEO Mark Pruzanski sold 1,532 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $58.87, for a total transaction of $90,188.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Daniel G. Welch sold 217 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $126.76, for a total value of $27,506.92. Following the transaction, the director now owns 3,710 shares of the company’s stock, valued at approximately $470,279.60. The disclosure for this sale can be found here. Insiders sold a total of 6,920 shares of company stock valued at $672,822 in the last quarter. Corporate insiders own 9.20% of the company’s stock.
Institutional investors have recently bought and sold shares of the stock. WFG Advisors LP lifted its position in shares of Intercept Pharmaceuticals by 16.4% during the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 125 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Intercept Pharmaceuticals by 14.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 132 shares during the period. US Bancorp DE bought a new position in shares of Intercept Pharmaceuticals during the 1st quarter worth approximately $130,000. IFP Advisors Inc lifted its position in shares of Intercept Pharmaceuticals by 128.1% during the 2nd quarter. IFP Advisors Inc now owns 1,300 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 730 shares during the period. Finally, Quantbot Technologies LP bought a new position in shares of Intercept Pharmaceuticals during the 1st quarter worth approximately $170,000. Institutional investors and hedge funds own 82.19% of the company’s stock.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.